Kalaris Therapeutics, Stock Market Value
| KLRS Stock | 7.12 0.96 15.58% |
| Symbol | Kalaris |
Kalaris Therapeutics, Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kalaris Therapeutics,. If investors know Kalaris will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kalaris Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.71) |
The market value of Kalaris Therapeutics, is measured differently than its book value, which is the value of Kalaris that is recorded on the company's balance sheet. Investors also form their own opinion of Kalaris Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Kalaris Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kalaris Therapeutics,'s market value can be influenced by many factors that don't directly affect Kalaris Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kalaris Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Kalaris Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kalaris Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Kalaris Therapeutics, 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Kalaris Therapeutics,'s stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Kalaris Therapeutics,.
| 09/10/2025 |
| 12/09/2025 |
If you would invest 0.00 in Kalaris Therapeutics, on September 10, 2025 and sell it all today you would earn a total of 0.00 from holding Kalaris Therapeutics, or generate 0.0% return on investment in Kalaris Therapeutics, over 90 days. Kalaris Therapeutics, is related to or competes with Cyclerion Therapeutics, XTL Biopharmaceutica, Alaunos Therapeutics, Pasithea Therapeutics, Quoin Pharmaceuticals, PharmaCyte Biotech, and NovaBay Pharmaceuticals. Kalaris Therapeutics, is entity of United States More
Kalaris Therapeutics, Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Kalaris Therapeutics,'s stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Kalaris Therapeutics, upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 8.01 | |||
| Information Ratio | 0.0835 | |||
| Maximum Drawdown | 64.78 | |||
| Value At Risk | (11.38) | |||
| Potential Upside | 17.61 |
Kalaris Therapeutics, Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kalaris Therapeutics,'s investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Kalaris Therapeutics,'s standard deviation. In reality, there are many statistical measures that can use Kalaris Therapeutics, historical prices to predict the future Kalaris Therapeutics,'s volatility.| Risk Adjusted Performance | 0.0727 | |||
| Jensen Alpha | 0.7812 | |||
| Total Risk Alpha | (0.08) | |||
| Sortino Ratio | 0.0952 | |||
| Treynor Ratio | 1.14 |
Kalaris Therapeutics, Backtested Returns
Kalaris Therapeutics, appears to be very risky, given 3 months investment horizon. Kalaris Therapeutics, has Sharpe Ratio of 0.0968, which conveys that the firm had a 0.0968 % return per unit of risk over the last 3 months. By analyzing Kalaris Therapeutics,'s technical indicators, you can evaluate if the expected return of 0.9% is justified by implied risk. Please exercise Kalaris Therapeutics,'s Downside Deviation of 8.01, mean deviation of 6.35, and Risk Adjusted Performance of 0.0727 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Kalaris Therapeutics, holds a performance score of 7. The company secures a Beta (Market Risk) of 0.73, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Kalaris Therapeutics,'s returns are expected to increase less than the market. However, during the bear market, the loss of holding Kalaris Therapeutics, is expected to be smaller as well. Please check Kalaris Therapeutics,'s maximum drawdown, as well as the relationship between the skewness and day typical price , to make a quick decision on whether Kalaris Therapeutics,'s current price movements will revert.
Auto-correlation | 0.58 |
Modest predictability
Kalaris Therapeutics, has modest predictability. Overlapping area represents the amount of predictability between Kalaris Therapeutics, time series from 10th of September 2025 to 25th of October 2025 and 25th of October 2025 to 9th of December 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Kalaris Therapeutics, price movement. The serial correlation of 0.58 indicates that roughly 58.0% of current Kalaris Therapeutics, price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.58 | |
| Spearman Rank Test | 0.43 | |
| Residual Average | 0.0 | |
| Price Variance | 0.57 |
Kalaris Therapeutics, lagged returns against current returns
Autocorrelation, which is Kalaris Therapeutics, stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Kalaris Therapeutics,'s stock expected returns. We can calculate the autocorrelation of Kalaris Therapeutics, returns to help us make a trade decision. For example, suppose you find that Kalaris Therapeutics, has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Kalaris Therapeutics, regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Kalaris Therapeutics, stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Kalaris Therapeutics, stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Kalaris Therapeutics, stock over time.
Current vs Lagged Prices |
| Timeline |
Kalaris Therapeutics, Lagged Returns
When evaluating Kalaris Therapeutics,'s market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Kalaris Therapeutics, stock have on its future price. Kalaris Therapeutics, autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Kalaris Therapeutics, autocorrelation shows the relationship between Kalaris Therapeutics, stock current value and its past values and can show if there is a momentum factor associated with investing in Kalaris Therapeutics,.
Regressed Prices |
| Timeline |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Kalaris Stock Analysis
When running Kalaris Therapeutics,'s price analysis, check to measure Kalaris Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalaris Therapeutics, is operating at the current time. Most of Kalaris Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Kalaris Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalaris Therapeutics,'s price. Additionally, you may evaluate how the addition of Kalaris Therapeutics, to your portfolios can decrease your overall portfolio volatility.